Dr. Liang C. Dong CEO ™×☆ & CSO Dr. Liang C. Dong, co-founder, Chairman, and CEO o÷↔☆f WD Pharma, holds a Ph.D. f≠α¥ rom the Department of Bioengiδ<♣↕neering at the Unive± ±£rsity of Washington in the United☆βε> States. Dr. Dong has extensive experience in the→↔ development of novel drug delivery p↑♠δlatforms and 505(b)(2) products.€Ω₽± Dr. Dong has held senior management p ≈ ositions such as Senio$ r Research Fellow an÷>×÷d Director of Oral Prod$$©§ucts at ALZA and Johnson &' Johnson. Dr. Dong is an inventor on more≤↑ than 100 patents, includin"&♣g more than 50 issued≠↑∞₹ U.S. patents. | ||||
Dr. Jim Wei CM∑O Dr. Jim Wei, co-fo®♥under, CMO of WD Pharma, mentored by P₽rof. Dr. Robert π♦≠Vestal; completed₹÷ ← postdoctoral stu×∏♠±dies at the σ University of ↔''Washington and theλε≤★ National Cancer In₩§γ stitute. • 10 years of wor≠™γk experience ↕↕γ©;in the Office&nb$αsp;of Clinical Pharmacology&n©→<bsp;at the FDA's&n→₽φ✔bsp;Center for Drug Evaφ∞€luation and Research&nbs₹σ€p;(CDER); recipient&nb≤ ₩sp;of the U.S. FDA&α₩nbsp;Outstanding Servi&ε♠ce Award a¶nd the Frances O. 'Ω Kelsey Award&nbs§±ε↔p;for Drug Safety. • 10 years of work↓'±® experience at Medpa ≥ce as Senior Medica≈¥γl Director ∞for early ph>'ase clinical development.¶∑ • Over 30 years&nbβ→↑§sp;of professiona←♦₩'l experience in cli£Ωnical trials and&¥ε≤•nbsp;regulatory submission↑≠s in various countries and♦↑λ regions.” | ||||
Dr. Jingmin Shi Deputy General M✔λβanager, Quality Director Dr. Jingmin Shi, a founding member♣ε↓ and VP of WD Pharma, ho>βlds master of pharmacology from Fud ±×πan University School of Medicine, P≠£h.D. in clinical pharmacology f¶$βΩrom Shanghai University of Traditional λ±Chinese Medicine, pos∑§≈tdoctoral fellow at theπδ≥€ National Institutes of Health (NIH) inδ<≠ the United States, and a visiting ¥πscholar at Novartis Pharmaceuticals.₹₽™ • Deputy Chief Pharmacist, member of ★the Clinical Pharmacology Committ£←ee of the Shanghai Pharmaceutica€'☆l Association; formerly s♦$erved as the head of the Pharmacology →₹and Toxicology Department o ©f the Shanghai Institute for Drug C♥←≥&ontrol, director of th←←e Toxicokinetics Department aΩΩ$t the Center for Drug Safety Ev™→aluation, and an on-sit"δΩe inspection expert at th₹≈≈e Shanghai Municipal Fo♦σ☆¶od and Drug Administration.©₩ • She specializes in ph$↕armacokinetics and bioanalysis,שγ with over 30 SCI (S↓©cience Citation Index) publπ γications, and has extensiε≥®ve experience in research an∑>♠d development, patenti&>ng, and quality manageme↑♣£•nt. | ||||
Jing Fang Deputy General Manager, C↑÷™FO Ms. Jing Fang, CFO of WD P±×£¶harma, holds a bachelor&#φ₽≤ 39;s degree in finance. Sφ₽he is a certified publσ£ ic accountant, an enterpriseδ≤ risk management professiona$≠l, and has a professiona"♥l qualification in financial m↔←anagement for corporate leade>δ ₹rs. • She has over 20 year®©∏₹s of experience in stand↓εardized financial management, equλ↕♠☆ity investment managem$↑×ent, and real estate man♣•π↓agement within large state-owned ent→♦>∑erprises. • Served as a Chief Financial Offic♣β®er (CFO) and Deputy General Manager in ₽ several domestic and Hong Kong-listed✔☆ pharmaceutical companies, with☆λ☆δ extensive operational ma≈₹§₽nagement experience in the phar ✔¶maceutical industry. • Member of the CPPCC (Chinese People"¶'s Political Consultative C onference) in Pudong New Area. |
